Sign in
Stories
Centessa Pharmaceuticals' ORX750 for Narcolepsy
Share
AscellaHealth Forecasts Robust Outlook f...
Asia Pacific Epilepsy Therapeutic Market...
Doze™ Introduces Luxury Duvets with Prop...
Overview
API
Centessa Pharmaceuticals presents preclinical data supporting the potential of ORX750, its investigational orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy and other sleep-wake disorders. The data shows effectiveness in promoting wakefulness and reducing cataplexy at low doses in animal models, suggesting potential for broader sleep-wake disorders. Centessa plans to initiate clinical development in the future.
Ask a question
How might the development of ORX750 influence the treatment landscape for narcolepsy and related conditions?
How might the success of ORX750 impact the pharmaceutical industry's approach to narcolepsy and other sleep-wake disorders?
What are the potential implications of ORX750's potential for broader sleep-wake disorders?
Article Frequency
0.2
0.4
0.6
0.8
1.0
May 2023
Jul 2023
Sep 2023
Coverage